The underlying mechanism of ICI therapy efficacy with increased TMB likely relates to the higher proportion tumour-specific neoantigens that develop as a consequence of increased TMB [106], which can then be displayed on major histocompatibility complex (MHC) molecules of the tumour cell and recognised by T cells [107]. This evidence concerns the gene HLA-C and neoplasm.